Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485407 · ClinicalTrials.gov registry record · Phase 3
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 377
- Enrollment target
NCT00485407 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 377 participants.
The verdict
NCT00485407, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 377 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
Interventions
- DRUG Atomoxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00485407
The ClinicalTrials.gov registry entry for NCT00485407 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine Hydrochloride is the first listed.
NCT00485407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00485407 about?
NCT00485407 is a clinical study titled "Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine". The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
What is the current status of trial NCT00485407?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2003-07. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00485407?
The interventions under investigation include: Atomoxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00485407?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.